Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Actinogen Medical Limited ( (AU:ACW) ) has issued an announcement.
Actinogen Medical Limited announced a General Meeting of Shareholders scheduled for March 14, 2025, encouraging participation through proxy forms and pre-submitted questions to facilitate a productive session. The company is advancing its clinical trials for Xanamem, a novel therapy targeting elevated cortisol levels in the brain, which has shown promising results in treating Alzheimer’s and depression, potentially impacting the market for neurological disease treatments.
More about Actinogen Medical Limited
Actinogen Medical Limited is an ASX-listed biotechnology company focused on developing therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a potential treatment for Alzheimer’s Disease and Depression, with future studies planned for Fragile X Syndrome and other conditions.
YTD Price Performance: 25.00%
Average Trading Volume: 258,775
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $60.89M
For an in-depth examination of ACW stock, go to TipRanks’ Stock Analysis page.
